Macrochemia ist heute 27% raufgegangen als Reaktion auf diese Nachricht. Genaues ist daraus aber nicht gerade rauszubekommen. Kennt jemand genaueres?
MacroChem Announces Pfizer Will Evaluate Feasibility of Improving Skin Penetration of Drugs Using MacroChem's Topical Absorption Enhancer
PR Newswire
Monday October 16 12:17pm
LEXINGTON, Mass., Oct. 16 /PRNewswire/ -- MacroChem Corporation (Nasdaq: MCHM) announced today that it has signed an agreement with Pfizer, Inc., under which Pfizer will evaluate the feasibility of using MacroChem's patented topical absorption enhancer, SEPA(R) to improve skin
absorption of a group of Pfizer pharmaceuticals.
Details and financial terms of the evaluation agreement were not disclosed.
MacroChem is a pharmaceutical company based in Lexington, MA that specializes in formulating drugs that can be administered through the skin. Following a capital infusion of more than $20 million in 1998, the company restructured itself from its contract R&D origins to develop proprietary
drugs based on its SEPA(R) technology. SEPA(R) temporarily neutralizes the absorption-barrier effect of the outer lipid layer of mammal skin, known as the stratum corneum.
MacroChem is currently conducting a 20-site, 460 patient pivotal phase 3 trial with Topiglan(R), its topical formulation of SEPA and Prostaglandin E1 for treating male erectile dysfunction. In addition to Topiglan(R), MacroChem is developing EcoNail(TM), a SEPA enhanced nail lacquer
for delivering antifungal agents through nails and surrounding tissues, for the 37 million Americans with onychomycosis, a fungal infection of the fingernails or toenails.
To the extent that this press release discusses matters relating to the development of future products, these are forward-looking statements and are subject to various risk factors that could cause actual results to differ materially from those expressed in the forward-looking statements. The
relevant risk factors are set forth in MacroChem's annual report on Form 10-K as filed with the SEC and include, without limitation, risks regarding product development, clinical trials, dependence on third parties for development and licensing arrangements, and risks involving regulatory approval of products, and licenses and patents.
MacroChem Announces Pfizer Will Evaluate Feasibility of Improving Skin Penetration of Drugs Using MacroChem's Topical Absorption Enhancer
PR Newswire
Monday October 16 12:17pm
LEXINGTON, Mass., Oct. 16 /PRNewswire/ -- MacroChem Corporation (Nasdaq: MCHM) announced today that it has signed an agreement with Pfizer, Inc., under which Pfizer will evaluate the feasibility of using MacroChem's patented topical absorption enhancer, SEPA(R) to improve skin
absorption of a group of Pfizer pharmaceuticals.
Details and financial terms of the evaluation agreement were not disclosed.
MacroChem is a pharmaceutical company based in Lexington, MA that specializes in formulating drugs that can be administered through the skin. Following a capital infusion of more than $20 million in 1998, the company restructured itself from its contract R&D origins to develop proprietary
drugs based on its SEPA(R) technology. SEPA(R) temporarily neutralizes the absorption-barrier effect of the outer lipid layer of mammal skin, known as the stratum corneum.
MacroChem is currently conducting a 20-site, 460 patient pivotal phase 3 trial with Topiglan(R), its topical formulation of SEPA and Prostaglandin E1 for treating male erectile dysfunction. In addition to Topiglan(R), MacroChem is developing EcoNail(TM), a SEPA enhanced nail lacquer
for delivering antifungal agents through nails and surrounding tissues, for the 37 million Americans with onychomycosis, a fungal infection of the fingernails or toenails.
To the extent that this press release discusses matters relating to the development of future products, these are forward-looking statements and are subject to various risk factors that could cause actual results to differ materially from those expressed in the forward-looking statements. The
relevant risk factors are set forth in MacroChem's annual report on Form 10-K as filed with the SEC and include, without limitation, risks regarding product development, clinical trials, dependence on third parties for development and licensing arrangements, and risks involving regulatory approval of products, and licenses and patents.
